Bosutinib for the Treatment of CML-Using it Safely: a Podcast.

Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) approved for use in patients with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic myeloid leukemia (CML), as well as Ph-positive CP, accelerated phase, or blast phase (with chemotherapy) CML resistant or intolerant to prior therapy. Clinical trials have shown bosutinib is effective as first-line therapy for patients with CML as well as in later lines of therapy after prior TKI failure. Bosutinib has an established safety profile; however, as with all TKIs approved for the treatment of CML, there are adverse events (AEs) that require management. The safety profile of bosutinib is characterized by gastrointestinal, hematological, hepatic, and skin toxicities. Many of these AEs can be managed with dose adjustment strategies. In this podcast, the authors summarize data from some recent bosutinib publications and discuss implications for optimizing bosutinib treatment of patients with CML. Podcast Video (MP4 210846 KB).